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Memoryal metabolic disorder and a degenerative disease of the central nervous system
respectively, it is now widely recognized that type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD)
share several common abnormalities including impaired glucose metabolism, increased oxidative stress,
insulin resistance and amyloidogenesis. Several recent studies suggest that this is not an epiphenomenon,
but rather these two diseases disrupt common molecular pathways and each disease compounds the
progression of the other. For instance, in AD the accumulation of the amyloid-beta peptide (Aβ), which
characterizes the disease and is thought to participate in the neurodegenerative process, may also induce
neuronal insulin resistance. Conversely, disrupting normal glucose metabolism in transgenic animal models
of AD that over-express the human amyloid precursor protein (hAPP) promotes amyloid-peptide aggregation
and accelerates the disease progression. Studying these processes at a cellular level suggests that insulin
resistance and Aβ aggregation may not only be the consequence of excitotoxicity, aberrant Ca2+ signals, and
proinﬂammatory cytokines such as TNF-α, but may also promote these pathological effectors. At the
molecular level, insulin resistance and Aβ disrupt common signal transduction cascades including the insulin
receptor family/PI3 kinase/Akt/GSK3 pathway. Thus both disease processes contribute to overlapping
pathology, thereby compounding disease symptoms and progression.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
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insulinemia, hyper-glycemia and hypo-responsiveness of the insulin
receptor (IR). Yet, T2DMhas a clear cognitive component that includes
impaired attention, memory and in the extreme, neurodegeneration
[1]. Impaired memory performance becomes particularly evident in
elderly T2DM patients [2]. With respect to epidemiology, each aspect
of insulin resistance in T2DM (e.g. hyperinsulinaemia, hyperglycemia,
glucose intolerance, adiposity, atherosclerosis, and hypertension) is an
independent risk factor for AD [3]. Thus clinical studies reveal that
patients who suffer from T2DM have a two- to three fold increased
relative risk for AD, independent of the risk for vascular dementia
[4–12].
AD is an age-related degenerative disease of the brain which is
characterized by progressive dementia and loss of other cognitive
abilities necessary for maintaining an independent living style.
Notably, greater than 80% of AD patients have T2DM or show
abnormal blood glucose levels [13]. Many excellent reviews have
covered the historical framework for the hypothesis that neuronal
insulin pathway is disrupted in both AD and T2DM [14–20]. The goal of
this article is to place more recent experimental data in the context of
this model, and underscore how each disease can contribute to the
progression of the other. The ﬁrst part of the article reviews the major
common cellular/molecular pathologies in T2DM and AD. The second
part summarizes experimental results illustrating interactions
between the CNS insulin receptor signaling and neuronal/synaptic
activities under physiological conditions, and the mechanistic bases
for potential development of neuronal insulin resistance. Finally, the
third part discusses the molecular interplay between neuronal insulin
resistance and amyloid β (Aβ) aggregation, a central molecular
pathology of AD. In this section, we will present experimental
evidence and theoretical foundation for a pathological loop formed
between insulin resistance and amyloidogenesis that drives AD and
T2DM progression.
1.1. Common pathological features between type 2 diabetes mellitus
(T2DM) and Alzheimer's disease (AD)
1.1.1. Glucose and energy metabolism impairment in T2DM and AD
The biological basis of T2DM is a systemic and chronic impairment
in glucose metabolism and utilization. Glucose metabolism is vital to
the brain, since glucose oxidation is nearly the exclusive energy source
required for neurons [21]. While representing only 2% of the body
weight, the brain consumes 18–30% of total body glucose [22].
Therefore, disruptions of glucose supply, transport, and utilization
result in neuronal damage and functional deﬁcits. Indeed, in the
developing human brain, hyperinsulinemia and hypoglycemia are
accompanied by neuronal death and excitotoxic process such as
seizure [23]. Severe chronic hypoglycemia can lead to permanent
brain damage and mental retardation [23]. T2DM has long been
shown to be associated with dementia [2,24–26]. The fact that
signiﬁcant cognitive disruptions are evident in elderly, but not
middle- or younger-aged T2DM patients [2,25,27] suggests T2DM-
originated pathologies (e.g. energy metabolism impairment and
microvascular lesion) interact particularly with aging. Experimental
diabetes in animal models shows a clear association of abnormal
glucose metabolism and impaired memory and synaptic plasticity
[25,28–36]. Thus disruptions in glucose metabolism can directly affect
cognitive function.
Extensive clinical studies have demonstrated that glucose meta-
bolism is also severely impaired in the cerebral cortex of the AD
patients using the PET tracer ﬂuoro-2-deoxy-D-glucose. The hypo-
metabolism is most prominent in the posterior cingulate and parieto-
temporal regions in early stages, but spreads to the prefrontal cortex
as the disease progresses[37–46]. The reduced glucose metabolism
can be detected in pre- or early stages of AD such as mild cognitive
impairment (MCI) cases [47,48]. More interestingly, similar hypo-metabolism is detected in young and middle aged individuals
carrying the apolipoprotein ApoE4 allele (who are at higher risk for
developing AD [49] prior to the ability of neuropsychological tests to
detect differences from normal individuals [38,39,50,51] and thus
may not only be attributable to neuronal loss. While neither ApoE4
nor brain glucose metabolism has been validated to predict AD
progression, results from these studies reveal an association between
abnormal glucose metabolism and an AD genetic risk factor.
Similarly, in transgenic animal models of AD, glucose metabolic
reduction is found in the posterior cingulate regions of the mouse
brain [52]. Disruptions of the amyloid precursor protein (APP), the
protein central to the molecular pathology of AD, either by deletion
[53] or expression of a human mutant [54,55] have been shown to
affect glucose metabolism and tolerance [56,57]. Finally, the glucose
transporter 1 (GLUT1), a major glucose transporter selectively
expressed in the endothelium of the blood brain barrier [58], is
signiﬁcantly reduced in aged humans and in transgenic mice and
coincides with hippocampal atrophy [59], suggesting impaired
glucose transport from the periphery into the CNS is correlated
with neuordegeneration. These data demonstrate that impaired
glucose distribution and utilization is a characteristic of AD.
1.1.2. Insulin resistance as a common molecular feature in both T2DM
and AD
Insulin resistance is a critical feature of T2DM that may be detected
10–20 years before the clinical onset of hyperglycemia [60–62]. Insulin
resistance is due to the reduced ability of the insulin receptor to
respond to insulin stimulation [62]. Under this condition, the islet β-
cells in the pancreas secrete higher levels of insulin to compensate for
the declined receptor function making hyperinsulinaemia a common
characteristic in T2DM patients. Although insulin receptors in the
brain have distinct structure and functions from their peripheral
counterpart [63], evidence indicates that excessive insulin levels are
associated with functional decline in the central nervous system
(CNS). For example, insulin levels usually rise with aging and are
strong predictors of cognitive impairment in adults without diabetes
[7,8,64]. Studies conducted with elderly subjects reported that elderly
men with the highest insulin levels made 25% more errors on the
Mini-Mental State Examination than men with the lowest insulin
levels [7,8,65]. In their study with postmortem brain tissues, Frolich
and colleagues ﬁrst reported an increase in insulin binding activity in
the brain regions of sporadic AD [66]. It is important to note, that
despite the increased insulin binding, insulin receptor activity was
reduced in the AD brain [67], consistent with insulin insensitivity.
Recently a study conducted by Steen et al [68] showed that gene
expression of a variety of molecules involved in insulin and insulin-
growth factor signaling pathways were altered in the AD brain. Based
on their ﬁndings, the investigators proposed that AD could be the type
3 diabetes [68]. Apart from the postmortem ﬁndings, Craft et al [69,70]
compared, in a clinical study, the plasma and CSF insulin levels
between 25 AD patients and 14 age-matched controls. Plasma
hyperinsulineamia was found in AD patients but not the age-matched
controls, providing compelling evidence for an association of insulin
resistance with AD. The association was further supported by
transgenic AD mouse models. At age of 13 month, Tg2576 mice
develop hyperinsulineamia in the plasma, which can be prevented by
treating the mice with an insulin sensitizer, rosiglitazone [57]. A
follow up study further showed that the rosiglitazone-corrected
euinsulinemia was accompanied by improved cognitive performance
in Tg2576 mice [71]. In addition, rosiglitazone also showed memory
preserving effect in mild AD patients reported by Watson et al in a
small scale clinical study [72]. Finally, factors that contribute to T2DM
accelerate Aβ deposition in AD mouse models [73] while improved
diet reduces Aβ deposition [74,75]. These data indicate that both
hyperinsulinemia and impaired insulin receptor functionwhich typify
T2DM, are also commonly found in AD.
484 W.-Q. Zhao, M. Townsend / Biochimica et Biophysica Acta 1792 (2009) 482–4961.1.3. Amyloidogenesis is a common pathological feature in both AD
and T2DM
Both AD and T2DM are amyloid forming diseases. Extracellular
amyloid plaque in the brain is one of the principal pathological
hallmarks of AD, in which the primary component is made by the
amyloid beta peptide1-42 (Aβ) originated from the amyloid precursor
protein (APP) via proteolytic cleavage [76,77]. Similarly, deposits of an
amyloidogenic peptide are found in the pancreatic islets of Langerhans
of T2DM patients. Although it was less well characterized compared to
other diabetic pathological changes such as hyperglycemia and
hyperinsulinaemia, the islet amyloid was found by ultra structural
study, to contact β-cells of the T2DM islet [78]. The component of the
islet amyloid deposit was subsequently identiﬁed as a 37-amino acid
peptide and thus named islet amyloid polypeptide (IAPP) or amylin
[79,80]. Under physiological conditions, IAPP is made in islet β-cells
and co-secreted with insulin in a ﬁxed ratio. It acts as both an
adiposity and a satiety signal, combining functional aspects of insulin
and glucagon in regulation of food intake and body weight [81,82].
Both human Aβ and IAPP exhibit sequence differences from their
respective counterparts in mice [83]. While the human Aβ1-42 and
IAPP are highly prone to aggregation, the mouse Aβ peptides and IAPP
do not form polymers [84]. As with AD mouse models that
overexpress human APP and develop amyloid plaques, mice trans-
fected with human IAPP together with diabetic traits develop IAPP
oligomers and ﬁbrils in the islet and show more severe diabetic
symptoms [85]. This subject will be discussed in further details in
section 3.4.
The evidence of Aβ oligomer toxicity on neurons together with
multiple common features of IAPP with Aβ suggested that aggregates
of IAPP could generate toxicity to islet β-cells in a way similar to Aβ
oligomers do to neurons. Extensive studies in the past years have
found that like Aβ1-42, IAPP also forms early intermediate assemblies
as spherical oligomers [86,87] that are recognized by a soluble Aβ
oligomer antibody [88] implicating that these oligomers possess a
common folding pattern or conformation. The behavior of IAPP
oligomers toward cultured β cells is similar to Aβ oligomers to
neurons [89–93]. While the in vivo “true” IAPP oligomers remain to be
isolated from the T2DM islets, these in vitro and ex vivo studies
suggest a potential role of IAPP soluble oligomers in degeneration of
the insulin producing β-cells in T2DM. Thus, although the nature of
the toxic oligomer species and the mechanism by which they cause
target cell damage have not been clearly understood, current evidence
supports the notion that amyloid formation might be a basic cause for
both AD and T2DM, as well as other protein deposition diseases [94–
97].
1.1.4. Elevated advanced glycation end products (AGEs) and oxidative
stress are commonly shared by T2DM and AD
Another common molecular pathology share by both T2DM and
AD is elevated levels of advanced glycation end products (AGEs) and
the related oxidative stress. In late stage T2DM, chronic intermittent
hyperglycemia leads to acceleration of AGEs generated by non-
enzymatic glycation and oxidation of cellular proteins, lipids and
nucleic acids by reducing sugars [98–103]. Both clinical and animal
studies have shown that elevated blood glucose levels result in
marckedly increased accumulation of AGEs in tissues of diabetic
subjects [98,104–107]. Besides hyperglycemia, aging and increased
oxidative stress contribute signiﬁcantly to AGE formation [101,108].
Accumulated AGEs bind to the cellular receptor (RAGE), a member of
the immunoglobulin sperfamily that is expressed on multiple cell
types including endothelial cells, mononuclear phagocytes, vascular
smooth muscle cells and microglia [109]. Interactions of AGEs with
RAGE trigger signaling cascade involving upregulation of transcription
factor NF-κB [110]. This process leads to further increased oxidative
stress and production/secretion of high levels of inﬂamtory cytokines
such as IL-6 and TNF-α [98]. Thus the AGE-RAGE interactionrepresents an important source of inﬂamation and oxidative stress,
and is associated with diabetic complications such as diabetic
retinopathy, neurophathy, and cardiovascular lesions [98].
Accumulation AGE is not unique to diabetes, but is closely
associated with aging and neurodegenative disease such as Alzhei-
mer's disease [101–103,108,111–113]. Modiﬁcation of Aβ by AGE
markedly accelerates Aβ aggregation [114]. Glycation of tau stabilizes
neuroﬁbrillary tangles [115–117]. High levels of AGE immunoreactivity
are present in AD plaques and neuroﬁbrillary tangles [101,114,118–
121]. This evidence indicates that accumulation of AGE in the brain
contributes to amyloidosis and neuroﬁbrilarry tangle formation.
Moreover, present in brain endothelium, microglia and neurons,
RAGE has been found to be a receptor for Aβ [122,123] and mediates
Aβ induced microglia activation and subsequent inﬂammation in AD
[124–129]. Interaction of Aβwith RAGE in neurons has been reported
to mediate Aβ-induced disruption of LTP [130]. These data implicate
elevated glucose levels in AGE-associated neurodegenerative
processes.
2. Current understanding of the brain insulin receptor functions
Because neurons do not require insulin for glucose transport, the
brain was considered a non-insulin targeting organ until approxi-
mately 30 years ago whenwidespread distribution of insulin receptor
(IR) was detected in the brain [131,132]. A speciﬁc regional expression
of IR mRNAwith situ hybridization [133,134] and insulin binding with
autoradiography [135] revealed that IRs are distributed in discrete
areas including the olfactory bulb, pyriform cortex, hippocampus,
amygdala, and hypothalamus. The highest concentrations of IR mRNA
expression was found in the choroid plexus and cerebellum [100–
102]. Interestingly, while the cerebellum has high levels of IR mRNA,
only low levels of protein are detectable [101,102], presumably due to
a high protein turnover rate of the receptor. At cellular/subcellular
levels, IRs are enriched in neurons relative to the glia, and
concentrated in synaptic membranes [135,136]. There is some
evidence that insulin itself is expressed in the CNS [137–141] [352],
albeit at low levels. Nevertheless, the role of CNS produced insulin is
poorly understood.
Biochemical characterization of brain IRs indicates that bymultiple
criteria they are similar to the peripheral IR [142], yet they display a
couple of key differences. First, due to alternative splicing, brain IRs
have a lower molecular weight [143,144]. This is caused be deletion of
the exon 11 encoding a sequence of 12 amino acids at the distal end of
the α subunit [145–148]. IRs lacking exon 11 (A type) show a higher
insulin binding afﬁnity, differential glycosylation and a higher
internalization rate than the exon 11-containing IR [149,150]. More-
over, a prominent functional difference between the brain and
peripheral IRs is that brain IRs are dispensible as the primary and
direct regulator of glucose transport and metabolism [151–153].
Instead, brain IRs exert diverse functions determined by the brain
region where they are localized. The preponderance of evidence
suggest that major functions of brain IR signaling include the central
regulation of body energy homeostasis, modulation of synaptic
plasticity and cognition, and involvement in aging-related
neurodegeneration.
2.1. Central control of food intake and energy homeostasis
One of the most extensively studied and so far best deﬁned
functions of the CNS IR is its central role in governing the body energy
homeostasis exerted by insulin signaling from hypothalamus.
Although the role of CNS insulin signaling in regulation of food intake,
body weight control and reproduction has long been proposed [154–
156], it has only been clearly conﬁrmed recently that mice with
selective deletion of neuronal insulin receptor (NIRKO) display food
intake-dependent obesity and impaired reproduction [157]. While
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review, readers are referred to excellent review articles for detailed
information [158–163].
2.2. Insulin receptor in cognition
Less understood are roles of CNS IRs in learning and memory. The
abundant distribution of IRs in hippocampus, amygdala and cerebral
cortex suggests that they play a role in synaptic activity and cognitive
process. Indeed, animals experiencing spatial learning show an
increased amount of insulin receptor [101] and insulin substrate-1
(IRS-1) [119] in synaptic membranes of the hippocampus. On the
other hand, rats with deﬁcits in β cell insulin production resulting
from experimental diabetes show reduced insulin receptor in their
hippocampus [32]. Insulin, when given to healthy human adults under
euglycemic clamp to maintain normal blood glucose levels, results in
activation of medial temporal lobe including the hippocampus
revealed by functional MRI (fMRI) [164], a structure critically required
for processing declarative memory [165]. Consistent with the induced
brain activation, insulin was shown to exert cognition-enhancing
effects in both human and experimental animals [166–169]. In recent
years, a new delivery method of insulin has been tested, in which
insulin is administered via an intranasal route to avoid insulin's
peripheral effects. Individuals receiving insulin via this method show
an elevated CSF insulin level, but unaffected plasma insulin levels
[170] together with enhanced declarative memory such as recalling
previously learned words [170,171]. Intranasal insulin administration
improves attention and verbal memory of AD patients and individuals
with MCI [172]. However, the treatment was shown to be only
beneﬁcial to non-ApoE4 carriers [173]. Involvement of insulin
signaling in learning may be evolutionarily conserved in C elegans
[174]. Insulin-1 was found to be localized in AIA interneurons of C
elegans and required for chemotaxis learning [141].
2.3. Insulin signaling in synaptic plasticity — a modulator of the
membrane excitability homeostasis?
Precisely how insulin signaling is involved in memory processing
has been a topic of research for the past decade. Electrophysiology
studies have revealed a role of synaptic signaling in long-term
potentiation (LTP) and long-term depression (LTD), two primary
well characterized forms of activity-dependent synaptic plasticity in
the mammalian CNS [175–177]. Using a streptozotocin-induced
experimental diabetic animal model, several studies have shown
that both spatial learning and hippocampal LTP are inhibited in
diabetic animals [29,145]. The LTP deﬁcit was prevented by insulin
treatment [178]. Also observed in these animals was a marked
decrease in the NR2B subunit of NMDA receptor [179]. While the
severity of LTP deﬁcits was related to hyperglycemia [29] implicating
an indirect effect, direct inhibition of IR activity via the IR tyrosine
kinase inhibitor AG1024 disrupts LTP in hippocampal brain slices
[180]. However, a recent study by Stranahan et al suggests that
diabetes-associated memory and LTP deﬁcits may be mediated by a
glucocorticoid-mediated mechanisms [36].
Multiple studies have demonstrated that insulin regulates inhibi-
tory transmission and synaptic depression pathway by regulating
AMPA and GABA receptor trafﬁcking. The AMPA-type glutamate
receptor mediates the vast majority of fast excitatory transmission at
CNS synapses. They are the primary receptors responsible for basal
synaptic transmission, activation of NMDA-type glutamate receptors,
as well as expression of LTP and LTD [181–184]. Synaptic AMPA
receptors are highly dynamic, showing rapid exocytosis and endocy-
tosis [185]. Research over the past decade has reached a general
consensus in the ﬁeld that it is the regulated, rather than constitutive
or ligand-induced endocytosis of AMPA receptor mediated via a
clathrin-dependent mechanism, that reduces the number of thereceptors on synaptic membrane surface and underlies synaptic LTD
[186,187]. Using electrophysiology, molecular mutagenesis, pharma-
cology and confocal immunostaining, several labs have independently
shown that application of insulin to neurons induces a rapid
internalization of AMPA receptor via a clathrin-mediated pathway
[188–191] thereby inducing LTD [152,155,157]. Moreover, insulin-
mediated LTD shares the same mechanism as low frequency
stimulation (LFS)-induced LTD, since these two types of LTD induction
occlude each other [155]. These experiments demonstrate that insulin
can regulate AMPA receptor trafﬁcking that underlies synaptic
transmission and synaptic plasticity. LTD mediated by AMPA receptor
internalization has been shown to regulate extinction of fear
conditionedmemory process [192], hence linking the insulin-involved
synaptic activities to speciﬁc aspects of cognition. The paradox that
insulin is found to promote both LTP and LTDwas addressed in a study
by van der Heide et al., in which the authors show that insulin shifts
the stimulation frequency threshold for inducing LTD and LTP. Thus in
the presence of insulin, 0.033 Hz and 10 Hz frequencies induce LTD
and LTP respectively while in the absence of insulin, 1 Hz and 100 Hz
frequencies are required [193]. These results suggest that insulin plays
a modulatory role in activity-dependent synaptic plasticity via
changes in membrane responsiveness to stimulation frequency.
Consistent with this ﬁnding, Chiu et al [194] reported that transfection
of a dominant-negative IR in optic neurons of Xenopus tadpole
decreased synaptic density and AMPA currents following visual
stimulation. These data indicate that insulin receptors in the CNS
play a role in regulating synaptic structure and function.
In addition to AMPA and NMDA receptors, insulin has been shown
to be a regulator of type-A GABA receptors. GABA(A) receptors are the
principal inotropic GABA receptor in the CNS and mediate inhibitory
synaptic transmission throughout the brain including hippocampus
and cerebral cortex. Using HEK 293 cells expressing GABA(A)
receptors, Wan and colleagues show that insulin causes a rapid
recruitment of GABA(A) receptors from cytosol to the plasma
membrane [195]. These receptors are functionally integrated into
the membrane, since the authors observe enhancement of GABA(A)
receptor mediated miniature inhibitory postsynaptic currents
(mIPSC) following insulin treatment [162]. Following these ﬁndings,
it is shown that insulin also affects muscarinic acetylcholine
transmission-potentiated GABA currents [196]. Essential to the
insulin-mediated effects on GABA neurotransmission and transloca-
tion is the PI3 kinase signal transduction pathway [197].
Similar to the effects of insulin on GABA receptors in the CNS,
insulin potentiates glycine signaling, another inhibibitory neurotrans-
mitter, in spinal cord neurons [198,199]. In the presence of insulin, the
amplitude, but not the frequency of glycine mIPSCs increases three
fold compared with untreated cells. As with GABA(A) receptors the
PI3K pathway is involved; however, insulin does not appear to cause
translocation of glycine receptor in spinal cord primary neurons [165].
While methods vary between laboratories (such as insulin concentra-
tion, acute versus chronic application, cell type), the preponderance of
evidence obtained so far points to a role for insulin and insulin
receptors in the cycling of multiple neurotransmitter receptors into
and out of synapses.
While in vitro studies suggest insulin receptors modulate multiple
neurotransmitter systems, in vivo studies using the NIRKO mice (with
selective deletion of neuronal insulin receptor) suggest only a modest
role for the neuronal insulin receptors. Schubert et al. reported that
these mice showed no deﬁcits in learning tasks such as the Morris
water maze or T-maze, nor alteration of brain glucose metabolism
despite altered PI3K signaling and GSK3 activity [118]. Although a
clear understanding has not been achieved, one explanation is that the
hippocampus and the cerebral cortex express the IGF-1 receptor.
Under physiological conditions, insulin and IGF-1 cross-react with IRs
and IGF-1Rs. Moreover, the IR family shares many intracellular
signaling pathways. The IR family is also thought to form heteromeric
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IGF-1 receptor levels were reported to be unchanged in the NIRKO
mice, it is possible that the IGF-1 receptor could compensate for the
lack of IRs. Indeed, in diabetic rats with severe insulin deﬁcits, we have
observed decreased IR expression accompanied by a slight but
signiﬁcant upregulation of IGF-1R in the hippocampus [32]. Given
the amount of tau pathology in the NIRKO mice, it is surprising that
these animals appear to be cognitively normal. However it is worth
noting that the T2DM-associated cognition impairments mostly are
not evident until age 65 or older [2,7,8,25,27,66], and that memory
deﬁcits in diabetic animals depend on disease duration [201].
Additional studies, therefore, with aged mice (the NIRKO mice were
7 weeks old) might reveal more evidence of abnormal cognitive
functions. Alternatively, an inducible siRNA knockdown of brain
insulin and/or IR/IGF-1R could provide complementary data.
2.4. Regulation of insulin receptor activity by synaptic/neuronal activities
— implication of excitotoxicity and neuronal insulin resistance
Much effort has been devoted to the effects of insulin signaling on
synaptic and neuronal function. In contrast, little is known about how
IRs in turn affected by synaptic activity. Studies on peripheral IRs
reveal that IR tyrosine phosphorylation is regulated by multiple
feedforward and feedback routes at both inter- and intra-molecular
levels.
The IR is a membrane receptor tyrosine kinase, activated by
tyrosine autophosphorylation of the β subunit upon insulin binding to
the α subunit exposed to the extracellular surface [202,203]. The
phosphorylated receptor subsequently activates several downstream
signaling cascades primarily through insulin receptor substrates 1–6
(IRS1-6). Best studied in the periphery, activated IRs initiate signaling
through phosphoinositide 3-kinase (PI3K), PDK-1 and Akt/PKB [204].
Activation of this pathway leads to several responses: 1) GLUT4
translocation to the plasma membrane for glucose transport and
uptake [205]; 2) glycogen synthesis-via Akt inhibition of GSK3, a
kinase that is constitutively active and negatively regulates glycogenFig. 1. Hypothetical schematic showing synaptic interactions of insulin receptor with neurot
glutamate receptor triggers a depolarization of the synaptic membrane. In response to the sh
dependent Mg2+ block and coupled with glutamate binding, results in activation of the NM
secondmessenger to trigger activation of a variety of Ca2+-dependent protein kinases that ar
insulin activation of insulin receptors (IRs) activates endocytotic pathways to internalize syn
long-term depression (LTD) similar to that induced by low concentrations of Ca2+ (LCa2+). A
receptors to the membrane surface. The balance of glutamatergic and GABAergic transmissio
involved in regulating the relative strength of synaptic inputs required for the storage of mem
membrane as well as synaptic plasticity. At the same time, IR function is affected by synap
inhibitory effect on IR tyrosine kinase function by increasing serine and threonine phosphor
found in AD, insulin receptor function may be adversely affected, thereby contributing to dsynthase [206]; and 3) lipogenesis via up-regulation of fatty acid
synthase gene [207].
Under physiological conditions, deactivation of IRs is regulated by
multiple tyrosine phosphatases including the protein tyrosine
phosphatase-1B (PTP1B) [208,209]. Secondly, IR activity can be
inhibited by serine/threonine (Ser/Thr) phosphorylation at the level
of IR itself or on downstream signaling molecules such as IRS-1 [210–
219]. For instance calcium has been shown to inhibit IR autopho-
sphorylation subsequent to insulin binding [185], primarily via the
activation of Ca2+-dependent Ser/Thr kinases such as PKC, Akt and
MAP kinase [220–225]. Thirdly, IRs are regulated by receptor
internalization, downregulation and desensitization. Upon insulin
binding, IRs undergo rapid internalization to endosomes where they
dissociate from insulin and are degraded [226–228] or recycled back
to the plasma membrane [229,230].
Based on this evidence, it is likely that IRs in the brain can be
negatively regulated by Ca2+ inﬂux subsequent to excitatory or
excitotoxic neurotransmission. Activation of excitatory glutamatergic
receptors such as NMDA receptor induces Ca2+ inﬂux at postsynaptic
sites, which acts as a second messenger to stimulate an array of Ca2+-
dependent Ser/Thr protein kinases such as PKC, Ca2+/calmodulin-
dependent kinase II (CaMKII), MAP kinases and Akt [231–241].
Indeed, in the presence of elevated calcium, insulin-stimulated IR
tyrosine phosphorylation is markedly reduced in hippocampal
synaptic preparations [101]. In hippocampal primary neuronal
cultures, both glutamate and high K+ induced depolarization have
been shown to attenuate insulin-stimulated IR tyrosine phosphoryla-
tion. The effect is reversed by the NMDA receptor antagonists APV and
memantine; neuronal activity blocker tetrodotoxin, and calcium
chelator BAPTA-AM[242]. Thus, at hippocampal synapses, IRs not
only modulate glutamatergic and GABAergic transmission, but are
also regulated by calcium and calcium-dependent kinases arising from
synaptic transmission (Fig. 1).
The negative regulation of IR tyrosine phosphorylation by calcium
and calcium-dependent kinase activities suggest a testable model for
the molecular basis brain insulin resistance under pathologicalransmitter receptors. Upon binding of the neurotransmitter glutamate, the AMPA-type
ift in membrane potential, NMDA-type glutamate receptors are relieved of the voltage-
DA receptor and Ca2+ inﬂux. The high concentration of Ca2+ (HCa2+) inﬂux acts as a
e required for formation andmaintenance of long-term potentiation. On the other hand,
aptic AMPA receptors. Removal of AMPA receptor from the synapses is associated with
ctivation of insulin signaling also potentiates GABA transmission by recruiting GABA(A)
n are required to maintain proper brain function, while LTP and LTD-like processes are
ory. Therefore, IR signaling may play a role in modulating the excitability of the synaptic
tic activity. Ca2+-dependent kinases that are activated by synaptic activity can exert a
ylation of IRs and/or IR substrates. Under conditions of abnormal Ca2+ regulation, often
ecreased insulin sensitivity.
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calcium deregulation are thought to be involved in pathogenesis of
neurodegenerative diseases such as AD [243–246]. Persistent excito-
toxicity caused by high levels of glutamate neurotransmission and
abnormally elevated calcium signal could enhance Ser/Thr phosphor-
ylation of the IR and IRS, thereby attenuate IR tyrosine kinase activity
and downstream insulin signaling. In return, impairment of insulin
signaling could compromise synaptic trafﬁcking of AMPA receptors
(endocytosis) and GABA(A) receptors (membrane translocation).
Together with disregulation of other insulin-modulated membrane
proteins (Na+/K+ ATPase, for example) [247], this feeback loop
could adversely affect the maintenance of synaptic membrane
potential thereby further exacerbating the cell's control of membrane
excitability.
3. Involvement of insulin signaling in AD pathogenesis:
Interaction of brain insulin resistance and Aβ aggregation
3.1. Aβ abnormality in AD and the synaptotoxicity of Aβ oligomers
The most evident symptom of AD is a progressive memory loss.
Although the etiology and epidemiology for the early onset (EOAD)
and late onset AD (LOAD) may be quite different, the clinical
symptoms and brain pathologies for both are indistinguishable with
deposition of senile plaques in the parenchyma and vasculature
accompanied by neuroﬁbrillary tangles (NFT) in the intraneuronal
compartment. Because of the common pathology, it is widely believed
that Aβ plays a key role in the molecular mechanisms of early disease
progression [248–250].
The Aβ1-40 and Aβ1-42 peptides are produced from sequential
enzymatic cleavages of APP by the β-site amyloid precursor protein
cleaving enzyme-1 (BACE-1) and the γ secretase complex [249]. Early
onset AD is caused by mutations of APP [251,252] and presenilins 1
and 2 [253–256], which typically increase the levels of Aβ or
propensity of Aβ to aggregate. The mechanism for accumulation of
Aβ in LOAD, however, is not clear. It has been suggested that cleavage
of the wild-type APP occurs at the endosome and/or along the
endocytic pathway, since high efﬁciency of APP-BACE interactions are
found in the endosome but not the trans-Golgi Network (TGN) and
cell surface [257,258]. One hypothesis is that additional genetic factors
including molecules that affect protein sorting within the endosome-
TGN and/or endosome-membrane routes contribute to prolonging
APP-BACE interactions which result in increased Aβ production [229].
In many cases, the genetic risk factors for AD are expected to elevate
Aβ levels or the propensity for aggregation of Aβ in the brain.
It is generally believed that accumulation of Aβ leads to its
aggregation, and it is these misfolded Aβ species that are detrimental
to neuronal networks [259–262]. Compared to Aβ1-40, Aβ1-42 has
high propensity to aggregate rapidly [263–265], forming multi-level
intermediates from oligomers, protoﬁbrils to plaque [250]. Among the
multi-forms of Aβ1-42, the soluble oligomers have been shown over
the past 10 years to be the most toxic species to neurons [266,267]. In
the brains of MCI patients that are not contaminated with senile
plaques, the Aβ levels correlate with cognitive decline [268]. From the
brain and CSF of AD patients, ADDLs, a term describing a combination
of Aβ oligomeric species from trimer to 24mer or higher [269,270] are
found to be markedly increased compared to age matched non-
demented controls [271,272]. Similarly, in AD transgenic mice over-
expressing mutated human APP, increases in Aβ production correlate
closely with memory deﬁcits in middle aged mice before plaque
formation [54]. From both human AD brain and brains of transgenic
mice, Aβ oligomeric species around 50–56 kDa (equal to approxi-
mately 12 aggregated monomers) have been identiﬁed to exert
neuronal toxic and memory impairing effects [273–275]. In addition,
naturally secreted small Aβ oligomers (e.g. dimers and trimers) are
also highly toxic to neurons [262,276]. It has been shown that smalloligomers of Aβ, probably formed ﬁrst as dimers intracellularly [277],
are secreted into conditioned medium as stable dimers and trimers
[276]. When the isolated oligomers or the conditioned medium
containing these oligomers are applied to rat hippocampal slices or
given to live animals, they blocked the LTP type of synaptic plasticity
and inhibited memory formation [278,279]. These inhibitory effects
are prevented by anti-Aβ antibody, gamma-secretase inhibitors and
scyllo-inositol that inhibits the stability of Aβ oligomers [246,247].
Furthermore, Aβ dimers were also detected and isolated from human
CSF and brains of AD patients [280,281]. When given to animals and
hippocampal slices, the dimer-speciﬁc CSF and brain tissue extract
showed potent LTP and memory disrupting effects [248,249]. With
synaptic immunochemical approaches, Aβ oligomers are shown to
bind speciﬁcally to synaptic spines and cause disruptions to these
structures [282,283]. The binding and synaptotoxic effects of these
oligomers are blocked by anti-ADDL antibodies [284,285].
It is not yet clear why oligomeric forms of Aβ are particularly toxic
to synpases at nanomolar concentrations compared to the monomers.
For one thing, these oligomers are unusual structures that appear
prominently only in disease. They arise from protein misfolding due to
certain cellular mechanistic defects that have not been clearly
identiﬁed. During oligomerization, Aβ monomers are likely to
undergo conformational changes [286] that may confer the ability to
interact with surface receptors such as IRs and α7nAchRs [287] which
could disrupt normal cellular function. In this scenario, a conforma-
tional change in oligomerized Aβ acts as a “gain-of-function'
pathogenic ligand [240,313] on surface receptor/proteins leading to
interruptions of normal neuronal function such as synaptic transmis-
sion and memory formation. Alternatively, oligomeric Aβ may be
more toxic than its monomeric form because an enlarged peptide may
sterically hinder the function of a membrane-bound protein such as a
ligand gated receptor. In either case, synaptic transmission and
downstream cellular events required for memory processing are
likely to be interrupted (i.e. synaptic failure) and memory formation
deﬁcits would occur [95].
3.2. Neuronal insulin receptor impairment as a direct target of Aβ
oligomer toxicity
Although the molecular mechanisms by which Aβ and its
oligomers induce synaptic degeneration and memory loss have yet
been clearly understood, evidence is now emerging that neuronal
insulin resistance in the AD brain is a direct consequence of Aβ
oligomer toxicity. As described in the previous sections, impaired
insulin receptor activity and plasma hyperinsulinemia are found in AD
patients and transgenic animal models of AD [57,69,70]. Treating AD
patients and transgenic animals with either insulin or insulin
sensitizer reduces Aβ level and improves memory performance
[71,139,140], suggesting a correlation between insulin resistance and
AD. More recent evidence has demonstrated that neuronal insulin
resistance is a direct consequence of Aβ oligomer toxicity. It is shown
that the low-n Aβ oligomers inhibit the insulin-stimulated IR tyrosine
phosphorylation and phosphorylation of several down stream kinases
in hippocampal neurons [147]. When applied to hippocampal slices
both Aβ oligomers and an IR tyrosine kinase inhibitor block LTP, an
effect that is overcome by 1 μM insulin [147]. Lee et al also reported
similar results, which showed that Aβ oligomers were signiﬁcantly
more potent than Aβ42 monomer in inhibiting LTP, and that insulin
overcame Aβ-induced LTP deﬁcits probably via inhibiting Aβ
oligomerization [288]. This synaptic plasticity protection of insulin is
consistent with insulin's memory improving function in AD patients
[139,140]. Independent results are also obtainedwith ADDLs. ADDLs at
nanomolar concentrations inhibit the insulin-stimulated IR tyrosine
phosphorylation in rat hippocampal primary neurons, and in human
IR expressing NIH3T3 cells [212]. Under the same condition, ADDLs do
not affect IGF-1R tyrosine phosphorylation. Remarkably, ADDLs'
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dendritic membranes; such that most ADDL bound neurons show the
IR immunoreactivity to be translocated to the cell interior and nucleus,
whereas neurons without ADDL binding showed intact IR immunor-
eactivities in dendrites [212]. A similar phenomenon appears to exist
in the AD brain. In a recent studyMoloney and colleagues [289] showa
loss of IR immunoreactivity from neuronal processes and the
periphery compartment of the cell body in brains of AD patients. In
these AD neurons IR immunoreactivity is localized in the nucleus,
whereas in neurons of non-AD brains the IR immunoreactivity is
detected in both neuronal processes and the cell body. In correlation, a
marked reduction in protein expression of IR and substrates IRS-1 and
IRS-2 were found in the brains of both AD patients and transgenic
animals [257]. Taking together, the evidence demonstrates IR
impairment (insulin resistance) can result directly from Aβ oligomer
toxicity, which may also be the situation in the AD brain.
3.3. Mechanisms by which Aβ oligomers induce neuronal insulin
resistance
Although it remains to be explored and clearly understood, several
mechanisms may underlie the Aβ oligomer-induced IR impairment.
3.3.1. A direct interaction between Aβ oligomers and IR
Aβ oligomers may disrupt IR function via a direct interaction. All
Aβ species including monomers [290], low-n oligomers [147], and
ADDLs [212] bind IRs. In one scenario Aβ has been proposed to
compete with insulin for IR binding thereby hindering IR activation
[258]. This is supported by the observation that insulin at a higher
dose (1 μM) overcomes the inhibition of LTP by Aβ oligomers [147].
Given the fact that both insulin and Aβ bind to and compete with the
same degradating enzyme (IDE) [291], it is possible that theymay also
compete for binding to the IR. By contrast ADDL binding to IR is
dependent on the tyrosine phosphorylation state of the IR [212].
Additional studies will be required to clarify whether and how Aβ
affects insulin binding, insulin receptor conformation and/or insulin
receptor expression (see below).
3.3.2. Downregulation of IR expression on synaptic membrane surface
Aβ oligomers may also disrupt synaptic IR function via removal of
the receptor from synaptic surface [212]. In addition to IR, Aβ has been
shown to cause loss of synaptic surface receptors including AMPA
[292], NMDA, α7-nicotinic receptors [255], and EphB2 tyrosine kinase
receptors [240]. The removal of most of these receptors is via Aβ-
triggered endocytosis [255,260], and it accompanies severe loss of
spine structures [240,247,249,260]. The IR is known to undergo rapid
internalization upon insulin binding, a mechanism is thought to
mediate insulin degradation and receptor downregulation [195]. It is
not clear whether loss of the synaptic IR is induced by a ligand-like
action of ADDLs, or simply an event accompanying synaptic spine
removal. However, the fact that insulin overcomes Aβ oligomer-
induced LTP inhibition [147] suggest a possible role for insulin
signaling in these processes. In any case, persistently suppressing IR
expression on neuronal surface may be an important mechanism by
which accumulated Aβ oligomers cause insulin resistance in the
brain.
3.3.3. Negative regulation by serine/threonine phosphorylation derived
from excessive excitatory activity and inﬂammation
Brain insulin resistance could be enhanced by Aβ oligomer-
associated excitotoxicity and inﬂammation. In the periphery, inﬂam-
matory factors such as TNF-α, free fatty acid (FFA) and their
downstream effectors such as the c-Jun amino-terminal kinases
(JNKs) have been identiﬁed as potent mediators for obesity-related
insulin resistance and T2DM [293–295] via inﬂuences on serine
phosphorylation of IR and IRS-1 [296,297]. Activities of PKC, Akt andseveral other kinases are involved in this pathway [298–301]. TNF-α
has been shown to inactivate phosphatase 1 (PP1) [302,303] shifting
the phosphorylation-dephosphorylation equilibrium to the left,
resulting in enhanced Ser/Thr phosphorylation of IRS-1 and IR.
Although largely unappreciated, Ser/Thr phosphorylation-induced
insulin resistance may be particularly relevant to the brain, as neurons
are the most polarized and excitable cells in the body and rely
critically on Ca2+ and Ca2+-dependent kinases for their functions. IR
and IRSs are highly concentrated on the synaptic membranes, the
primary sites where Ca2+ and other excitatory signals are generated,
which would subject them to regulation by synaptic activities. As
discussed earlier, increased Ca2+, neuronal depolarization and
glutamate have been shown to inhibit the insulin-stimulated tyrosine
phosphorylation of IR in hippocampal synaptic membranes and
primary neurons [101,212]. In addition to Ca2+ disregulation,
oxidative stress and inﬂammatory cytokines that are thought to be
involved in the pathogenesis of AD [102,302,304–308] could also
contribute to the inhibition of IR via increases in IRS and Akt serine
phosphorylation. Increased IRS-1 and Akt serine phosphorylation are
found in the AD brain and are correlated with decreased surface IR
expression and tyrosine phosphorylation [309]. Ex vivo studies show
that Akt activity is triggered by Aβ and Aβ oligomers [242,310], and is
responsible for mediating Aβ-induced microglia production of
inﬂammatory chemokines [311]. Given the negative feedback effect
of IRS-1 and Akt serine phosphorylation on IR Tyr phosphorylation,
the Aβ/Aβ oligomer-induced activation of IRS and Akt could
contribute to brain insulin resistance in AD. On the other hand,
PI3K/Akt pathway is well known as a downstream event to be
activated by IR and IGF-1R activities [170], which plays a role in
insulin and IGF-1- associated neuron protection [312–314]. Inter-
estingly, Akt activation is involved in both apoptotic and neuropro-
tective pathways mediated by different TNF receptors [315].
Therefore, depending on whether it is involved in a feedforward or
a feedback pathway, its cellular colocalization, and its speciﬁc
association with upstream signaling cascades, Akt serine phosphor-
ylation may induce different signal transduction outcomes.
3.3.4. Aβ oligomer induced insulin resistance at the blood brain barrier
and other brain regions
Aβ oligomers might cause insulin resistance in other brain cells.
For example, insulin receptor mRNA is highly concentrated at choroid
plexus [101–103] where it is responsible for transport of insulin across
the blood brain barrier [316]. Increased circulating Aβ oligomers in the
brain may act on IRs that are localized at brain capillaries, particularly
those at the choroid plexus. Impairment of IR at these loci would affect
central insulin transport. As brieﬂy mentioned earlier, Aβ oligomers
can also interact with RAGE in endothelial cells of blood brain barrier
to trigger production of inﬂammatory cytokines such as IL-6 and TNFα
[111,317]. Although AD most critically affects brain regions involved in
higher cognition, it is possible that at advanced stages more
widespread Aβ oligomers distribution in the brain circulation may
adversely affect neurons of other brain regions such as those in
hypothalamus or neurons with glucose sensing capability. If IRs in
these regions are impaired by Aβ oligomers, the result may be
disregulation of hypothalamic function, glucose and energy metabo-
lism. This might explain, at least in part, why a high proportion of AD
patients develop T2DM [13].
3.4. Insulin resistance as a necessary cofactor for Aβ aggregation – the
beginning of the vicious cycle?
While the above evidence shows that neuronal insulin resistance is
a result of Aβ oligomer toxicity, a large body of data indicates
impairment of brain insulin signaling promotes amyloidogenesis.
Insight may be gained from the generation of human IAPP (hIAPP)
transgenic mouse model. Although hIAPP is highly aggregable
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hIAPP do not produce islet amyloid aggregates despite up to 15-fold
increase in plasma hIAPP [318]. Nor do themice show any abnormality
in blood glucose and insulin levels [278]. However, when the hIAPP
mice islets are exposed to high concentrations of glucose in culture,
extracellular IAPP amyloid aggregates are formed [319]. Similarly, a
few years after their ﬁrst report in 1993 [278], Hoppener and
colleagues crossed the hIAPP mice with the ob/obmice (mice express
a mutant leptin gene and developed insulin resistance, obesity and
diabetes) to produce a double transgenic model [85]. Remarkably, a
signiﬁcant amount of islet amyloid aggregation was observed in the
islets of double transgenic hIAPP-ob/obmice together with additional
molecular, cellular and symptomatic alterations [85]. In ob/ob mice,
insulin resistance resulted in an increased insulin secretion that
overcomes hyperglycemia. In hIAPP-ob/ob mice, however, the hIAPP
amyloidogenesis is accompanied by exacerbation of insulin resis-
tance: The mice are notably more obese than ob/ob-only mice; and
insulin secretion is reduced resulting in hyperglycemia, indicating loss
of β-cell function. It is likely the loss of β-cells is caused by lower
molecular weight IAPP oligomers, which show cytotoxic effects by
disrupting membrane stability and inducing dell death in cultured
islet β-cells [86,88–90,92,93], similar to the neuronal toxic properties
of Aβ oligomers. On the other hand, the IAPP mature ﬁbrils are not
toxic [87,92]. From these results, it is suggested that increased hIAPP
production may be essential but not sufﬁcient for islet amyloidogen-
esis, whereas insulin resistance and elevated glucose is a necessary
cofactor required to triggers the amyloid aggregation. However,
whether and when an elevated IAPP level (locally and/or in
circulation) occurs in T2DM remains to be clariﬁed.
Similar cases can also be found in AD transgenic mice models. In
the Tg2576 AD mouse model, mice fed with normal laboratory diet do
not show memory deﬁcits until 6 months of age [54,55]. The mice
maintain relatively normal circulating insulin levels and glucose
metabolism until 13 months old, when plasma hyperinsulinemia
becomes evident [58]. Despite high production of Aβ and plaque
disposition, there is lack of neuronal death and neuroﬁbrillary tangles
in their brains [54,55]. However, when these mice are fed with a high
fat diet, they develop non-insulin dependent diabetes mellitus
(NIDDM) insulin resistance, a condition that leads to signiﬁcantly
advanced AD pathology and symptoms [73]. First, there is greater thanFig. 2. A hypothetical pathological loop of insulin resistance and Aβ accumulation: Increase
levels. First Aβ may disrupt insulin receptor function by downregulating membrane surface
Second, Aβmay inhibit of IR tyrosine kinase signaling by increasing intracellular Ca2+, there
Third, Aβ may induce microglia to produce inﬂammatory cytokines such as TNFα as well as
include accelerating disease progression, perhaps by activation of GSK3 leading to hyper
increasing Aβ production and impeding ransport and clearance of Aβ. Thus brain insulin re
more advanced stages.2-fold higher blood insulin levels by 9 months of age along with
obesity compared to the non insulin resistant Tg2576 mice that do not
show hyperinsulinaemia until 13 months of age [57]. Second, at the
same age, the levels of Aβ1-40 and Aβ1-42 from the hippocampus
and cerebral cortex are also N2-fold higher, correlated with activation
of γ-secretase and GSK3α and GSK3β. Third, the tyrosine phosphor-
ylation of cerebral IR is considerably lower, as is the phosphorylation
of PI3 kinase and Akt. Fourth, compared to the non insulin resistant
controls, the NIDDM insulin resistant Tg2576 mice show severe
impairment in water maze spatial learning [73]. Thus, similar to the
case of the hIAPP-ob/ob mice, on the basis of high production of Aβ,
development of insulin resistance accelerates brain amyloidogenesis,
and facilitates disease progression.
An impaired IR signaling may exacerbate Aβ accumulation in
several ways. Perhaps the most important effect of an impaired IR
signaling is reﬂected by a weakened inhibition on glycogen synthase
kinase 3 (GSK3), an important downstream node of IR signaling [320].
GSK3, including both the α and the β subunit, are thought to be
critically involved in AD pathogenesis with activated GSK3α trigger-
ing APP γ-secretase activity [321–324] thus increases Aβ production,
and GSKβ phosphorylating Tau [325–328] thereby promoting forma-
tion of NFT. Activation of IR signaling inhibits both GSK3α and SKG3β
via the PI3 kinase pathway [171]. Impairment of IR function, therefore,
would result in high activity of GSK3 that leads to enhanced Tau
phosphorylation and Aβ production, exacerbation of both would
certainly facilitate the disease pathologies. Indeed, speciﬁc knockout
of brain IR revealed activation of GSK3 in the mouse brain [118].
Secondly, brain insulin resistance could interrupt Aβ clearance. Aβ is
reported to be transported across the blood brain barrier and/or taken
into microglias for clearance, a process depending on the low-density
lipoprotein receptor-related protein (LRP) and its ligands ApoE and
α2-macroglobulin [329–332]. In addition Aβ is also cleared through
local enzymatic digestion by insulysin (IDE), neprilysin (NEP) and
other metalloenzymes [333–335]. Insulin signaling has been reported
to stimulate α2M binding to LRP and their expression [336] and
expression of IDE [337]. Furthermore, APP processing and Aβ
transport between TGN and plasma membrane in neurons has been
reported to involve IR signaling [338]. Insulin resistance, therefore,
would add to accumulation of Aβ via interruption of both clearance
and production processes (Fig. 2).d Aβ and Aβ oligomers in the brain may cause neuronal insulin resistance at multiple
IR via internalization, desensitizating the receptor or by direct substrate competition.
by activating select serine/threonine kinases, which in turn phosphorylate IRs and IRS.
its effectors free fatty acids (FFA) and JNK. The consequences of impaired IR signaling
phosphorylation of tau. Impaired IR function could also promote Aβ aggregation by
sistance and Aβ aggregation/accumulation reinforce each other to drive the disease to
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Emerging evidence in the past decade from the diabetes and AD
research ﬁelds, as well as from basic neuroscience research has made
great strides in understanding the molecular pathogenesis of these
two degenerative diseases. It is becoming clear that T2DM and AD are
linked by two common molecular pathologies, namely insulin
resistance and amyloidogenesis that are associated with impaired
glucose metabolism and increased oxidative stress. When they co-
occur in the brain, these two factors appear to form a pathological
loop, in which they interact with and reinforce each other to generate
cellular toxicity that leads to energy metabolism impairment and
cognitive deﬁcits. While IR impairment may result from actions of Aβ
oligomers at multiple levels, IR desensitization accelerates Aβ
aggregation and disease progression. Evidence supporting this loop
include that IR tyrosine kinase activity and its membrane surface
expression are markedly inhibited in the AD brain [67,289], and in rat
primary hippocampal neurons by Aβ oligomers [147,212]. Conversely,
T2DM is a risk factor for AD [339,340] . Insulin resistance is a trigger/
accelerator for amyloidogenesis[319] as transgenic mice on a insulin
resistance-inducing diet show more advanced Aβ deposition and
memory deﬁcits [73]. Therefore, not only do these diseases compound
each other's pathologies, but interact on the same molecular
pathways.
However, much is still unknown about the relationship between an
essential role of insulin signaling in normal cellular function and
development of T2DM and AD. One of the main issues that remains to
be reconciled is that deletion of the key IR/IGF-1 signaling (IIS) genes
in species including c. elegans [341,342], drosophila [343,344] and
rodents [345,346] during the embryonic development results in a
longer and disease-resistant life span [347], whereas diminished
insulin response of IR in later age is associated with metabolic/
degenerative diseases that cause high mortality. One possible
explanation is that with deletion of the key insulin pathway genes
throughout life, the body adopts a starvation strategy, upregulates
compensatory mechanisms and lengthens lifespan to improve
reproductive success. In contrast, insulin resistance in T2DM and AD
is a late onset dysfunction of glucose homeostasis. To clarify this issue,
novel animal models with inducible IR phosphorylation mutants
(either Ser/Thr or Tyr) may mimic the late onset insulin resistance
and thus provide a model to test this issue.
Another test of the hypothesis that insulin receptor signaling plays
an important role in AD, is the identiﬁcation of familial mutations in
the IR pathway that would increase the risk of developing AD. Point
mutations in IR are associated with insulin resistance, obesity and
diabetes [348–350]. Although one isolated study has identiﬁed
polymorphism of PI3K, a major downstream kinase of IR, in AD
patients [351], to date, no genetic defect of IR has been identiﬁed in
AD.
Additional questions include: How andwhy does insulin resistance
promote Aβ aggregation? Apart from inﬂuencing Aβ production and
Tau phosphorylation, does insulin resistance play a role in protein
misfolding on the neuronal surface? Does insulin resistance interfere
with Aβ turnover in the brain? To address these questions might
require development of appropriate animal models such as inducible
knockdown (or dominant negative) of IR in speciﬁc brain regions of
AD transgenic mice at speciﬁc age windows, from which the speciﬁc
molecular connection between brain insulin resistance and amyloi-
dogenesis relevant to disease progress of AD may be identiﬁed. If the
IR can affect synapses of the CNS, what is the source of endogenous
insulin (i.e. transport from the periphery, or locally synthesized and
secreted by neurons)? Is the mechanism of action direct through
insulin receptor signal transduction or perhaps indirect through
glucose metabolism and mitochondrial function? Lastly, while future
studies are required to validate the pathological feedback loops of
insulin resistance and amyloidogenesis, one can speculate that braininsulin resistance may contribute to abnormal Aβ turnover thereby
contributing to disease progression in at least a subtype of LOAD. Thus,
it may be reasonable to hypothesize that while the peripheral insulin
resistance likely to proceed into T2DM (some might take more than
10 years), the neuronal insulin resistance might proceed AD. In this
context, AD could be seen as a brain type of diabetes.
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